Myasthenia Gravis - Global Market Outlook (2017-2026)
According to Stratistics MRC, the Global Myasthenia Gravis Market is accounted for $1,215.00 million in 2017 and is expected to reach $3,651.25 million by 2026 growing at a CAGR of 13.0% during the forecast period. Increasing health care spending & improving health care infrastructure, increase in occurrence of autoimmune disorders and strong pipeline in its treatment are some of the key factors propelling the market growth. However, limited availability of FDA approved drugs and costly treatment options are some issues restricting the market growth.
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Moreover, it is characterized by fatigue and weakness of skeletal muscles. Therefore, it occurs in all races, males & females, and at any age. On the other hand MG is not thought to be directly hereditary nor is it transmittable. It does occasionally occur in more than one member of the same family.
Amongst treatment, drug treatment segment commanded considerable market share in the global market owing to the factors responsible for modifying the immune response of the immune system by inhibition of white blood cell activity. Based on geography, Asia Pacific region is expected to register highest market growth rate during the forecast period. Due to Several non-governmental and governmental organizations in the region are concerned in organizing awareness programs
Some of the key players in Myasthenia Gravis market include Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Valeant Pharmaceuticals International, Inc., Alexion Pharmaceutical Inc., F. Hoffmann-La Roche AG, CSL Behring, Baxter International, Inc., Avadel Pharmaceuticals, PLC. (Flamel Technologies) and Shire plc
Treatments Covered:
Myasthenia gravis is a chronic autoimmune neuromuscular disorder that is characterized by variable weakness of the voluntary muscle groups. Muscles that observe eye movement, shoulder & facial muscles, breathing & swallowing and eye lids are the ones that are regularly impacted in myasthenia gravis. Moreover, it is characterized by fatigue and weakness of skeletal muscles. Therefore, it occurs in all races, males & females, and at any age. On the other hand MG is not thought to be directly hereditary nor is it transmittable. It does occasionally occur in more than one member of the same family.
Amongst treatment, drug treatment segment commanded considerable market share in the global market owing to the factors responsible for modifying the immune response of the immune system by inhibition of white blood cell activity. Based on geography, Asia Pacific region is expected to register highest market growth rate during the forecast period. Due to Several non-governmental and governmental organizations in the region are concerned in organizing awareness programs
Some of the key players in Myasthenia Gravis market include Novartis AG, Takeda Pharmaceutical Company Limited, Grifols, S.A., Valeant Pharmaceuticals International, Inc., Alexion Pharmaceutical Inc., F. Hoffmann-La Roche AG, CSL Behring, Baxter International, Inc., Avadel Pharmaceuticals, PLC. (Flamel Technologies) and Shire plc
Treatments Covered:
- Rapid Immunotherapies
- Drug Treatment
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- France
- Italy
- UK
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
- South America
- Argentina
- Brazil
- Chile
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
1 EXECUTIVE SUMMARY
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Futuristic Market Scenario
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL MYASTHENIA GRAVIS MARKET, BY TREATMENT
5.1 Introduction
5.2 Rapid Immunotherapies
5.2.1 Thymectomy
5.2.2 Intravenous Immunoglobulin (IVlg)
5.2.3 Plasmapheresis
5.3 Drug Treatment
5.3.1 Chronic Immunomodulators
5.3.2 Monoclonal Antibodies
5.3.3 Cholinesterase Inhibitors
6 GLOBAL MYASTHENIA GRAVIS MARKET, BY GEOGRAPHY
6.1 Introduction
6.2 North America
6.2.1 US
6.2.2 Canada
6.2.3 Mexico
6.3 Europe
6.3.1 Germany
6.3.2 UK
6.3.3 Italy
6.3.4 France
6.3.5 Spain
6.3.6 Rest of Europe
6.4 Asia Pacific
6.4.1 Japan
6.4.2 China
6.4.3 India
6.4.4 Australia
6.4.5 New Zealand
6.4.6 South Korea
6.4.7 Rest of Asia Pacific
6.5 South America
6.5.1 Argentina
6.5.2 Brazil
6.5.3 Chile
6.5.4 Rest of South America
6.6 Middle East & Africa
6.6.1 Saudi Arabia
6.6.2 UAE
6.6.3 Qatar
6.6.4 South Africa
6.6.5 Rest of Middle East & Africa
7 KEY DEVELOPMENTS
7.1 Agreements, Partnerships, Collaborations and Joint Ventures
7.2 Acquisitions & Mergers
7.3 New Product Launch
7.4 Expansions
7.5 Other Key Strategies
8 COMPANY PROFILING
8.1 Novartis AG
8.2 Takeda Pharmaceutical Company Limited
8.3 Grifols, S.A.
8.4 Valeant Pharmaceuticals International, Inc.
8.5 Alexion Pharmaceutical Inc.
8.6 F. Hoffmann-La Roche AG
8.7 CSL Behring
8.8 Baxter International, Inc.
8.9 Avadel Pharmaceuticals, PLC. (Flamel Technologies)
8.10 Shire plc
2 PREFACE
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 MARKET TREND ANALYSIS
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Emerging Markets
3.7 Futuristic Market Scenario
4 PORTERS FIVE FORCE ANALYSIS
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 GLOBAL MYASTHENIA GRAVIS MARKET, BY TREATMENT
5.1 Introduction
5.2 Rapid Immunotherapies
5.2.1 Thymectomy
5.2.2 Intravenous Immunoglobulin (IVlg)
5.2.3 Plasmapheresis
5.3 Drug Treatment
5.3.1 Chronic Immunomodulators
5.3.2 Monoclonal Antibodies
5.3.3 Cholinesterase Inhibitors
6 GLOBAL MYASTHENIA GRAVIS MARKET, BY GEOGRAPHY
6.1 Introduction
6.2 North America
6.2.1 US
6.2.2 Canada
6.2.3 Mexico
6.3 Europe
6.3.1 Germany
6.3.2 UK
6.3.3 Italy
6.3.4 France
6.3.5 Spain
6.3.6 Rest of Europe
6.4 Asia Pacific
6.4.1 Japan
6.4.2 China
6.4.3 India
6.4.4 Australia
6.4.5 New Zealand
6.4.6 South Korea
6.4.7 Rest of Asia Pacific
6.5 South America
6.5.1 Argentina
6.5.2 Brazil
6.5.3 Chile
6.5.4 Rest of South America
6.6 Middle East & Africa
6.6.1 Saudi Arabia
6.6.2 UAE
6.6.3 Qatar
6.6.4 South Africa
6.6.5 Rest of Middle East & Africa
7 KEY DEVELOPMENTS
7.1 Agreements, Partnerships, Collaborations and Joint Ventures
7.2 Acquisitions & Mergers
7.3 New Product Launch
7.4 Expansions
7.5 Other Key Strategies
8 COMPANY PROFILING
8.1 Novartis AG
8.2 Takeda Pharmaceutical Company Limited
8.3 Grifols, S.A.
8.4 Valeant Pharmaceuticals International, Inc.
8.5 Alexion Pharmaceutical Inc.
8.6 F. Hoffmann-La Roche AG
8.7 CSL Behring
8.8 Baxter International, Inc.
8.9 Avadel Pharmaceuticals, PLC. (Flamel Technologies)
8.10 Shire plc
LIST OF TABLES
Table 1 Global Myasthenia Gravis Market Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 3 Global Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 4 Global Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 5 Global Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 6 Global Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 7 Global Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 8 Global Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 9 Global Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 10 Global Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 11 North America Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
Table 12 North America Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 13 North America Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 14 North America Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 15 North America Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 16 North America Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 17 North America Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 18 North America Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 19 North America Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 20 North America Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 21 Europe Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
Table 22 Europe Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 23 Europe Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 24 Europe Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 25 Europe Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 26 Europe Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 27 Europe Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 28 Europe Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 29 Europe Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 30 Europe Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 31 Asia Pacific Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
Table 32 Asia Pacific Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 33 Asia Pacific Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 34 Asia Pacific Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 35 Asia Pacific Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 36 Asia Pacific Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 37 Asia Pacific Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 38 Asia Pacific Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 39 Asia Pacific Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 40 Asia Pacific Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 41 South America Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
Table 42 South America Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 43 South America Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 44 South America Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 45 South America Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 46 South America Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 47 South America Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 48 South America Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 49 South America Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 50 South America Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 51 Middle East & Africa Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
Table 52 Middle East & Africa Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 53 Middle East & Africa Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 54 Middle East & Africa Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 55 Middle East & Africa Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 56 Middle East & Africa Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 57 Middle East & Africa Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 58 Middle East & Africa Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 59 Middle East & Africa Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 60 Middle East & Africa Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 1 Global Myasthenia Gravis Market Outlook, By Region (2016-2026) (US $MN)
Table 2 Global Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 3 Global Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 4 Global Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 5 Global Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 6 Global Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 7 Global Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 8 Global Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 9 Global Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 10 Global Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 11 North America Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
Table 12 North America Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 13 North America Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 14 North America Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 15 North America Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 16 North America Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 17 North America Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 18 North America Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 19 North America Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 20 North America Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 21 Europe Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
Table 22 Europe Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 23 Europe Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 24 Europe Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 25 Europe Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 26 Europe Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 27 Europe Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 28 Europe Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 29 Europe Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 30 Europe Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 31 Asia Pacific Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
Table 32 Asia Pacific Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 33 Asia Pacific Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 34 Asia Pacific Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 35 Asia Pacific Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 36 Asia Pacific Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 37 Asia Pacific Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 38 Asia Pacific Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 39 Asia Pacific Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 40 Asia Pacific Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 41 South America Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
Table 42 South America Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 43 South America Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 44 South America Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 45 South America Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 46 South America Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 47 South America Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 48 South America Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 49 South America Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 50 South America Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
Table 51 Middle East & Africa Myasthenia Gravis Market Outlook, By Country (2016-2026) (US $MN)
Table 52 Middle East & Africa Myasthenia Gravis Market Outlook, By Treatment (2016-2026) (US $MN)
Table 53 Middle East & Africa Myasthenia Gravis Market Outlook, By Rapid Immunotherapies (2016-2026) (US $MN)
Table 54 Middle East & Africa Myasthenia Gravis Market Outlook, By Thymectomy (2016-2026) (US $MN)
Table 55 Middle East & Africa Myasthenia Gravis Market Outlook, By Intravenous Immunoglobulin (IVlg) (2016-2026) (US $MN)
Table 56 Middle East & Africa Myasthenia Gravis Market Outlook, By Plasmapheresis (2016-2026) (US $MN)
Table 57 Middle East & Africa Myasthenia Gravis Market Outlook, By Drug Treatment (2016-2026) (US $MN)
Table 58 Middle East & Africa Myasthenia Gravis Market Outlook, By Chronic Immunomodulators (2016-2026) (US $MN)
Table 59 Middle East & Africa Myasthenia Gravis Market Outlook, By Monoclonal Antibodies (2016-2026) (US $MN)
Table 60 Middle East & Africa Myasthenia Gravis Market Outlook, By Cholinesterase Inhibitors (2016-2026) (US $MN)
